Neurocrine pens $880M deal with China’s TransThera for red-hot immunology target
Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in biobucks for inhibitors aimed at a red-hot inflammation target. San Diego-based Neurocrine secured…